Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima, Börje S. Andersson, Timothy Madden et al.|Blood|2004Cited by 422
Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow TransplantationCelso Arrais‐Rodrigues, Vanderson Rocha, Guillermo Sanz et al.|Journal of Clinical Oncology|2008Cited by 202